nejm glp 1 SCALE (NEJM 2015) was the pivotal trial for liraglutide 3.0 mg — the first GLP-1 RA approved for chronic weight management. In 3,731 adults with obesity, it produced 8.0% mean weight loss NEJM publishes Phase 3 trial

IGF-1 LR3 is utilized to investigate sustained IGF-1 receptor (IGF-1R) activation and downstream signaling pathways specifically PI3K/Akt/ mTOR and MAPK/ERK in controlled preclinical systems

But, for the most part, patients following standard protocol start with .25mg for the first four weeks and double the dosage in four-week increments until week 13 (e.g., 0.5mg weeks 5-8, 1mg weeks 9-12)

James Kim has conflicts in being either a member of an advisory board or speakers bureau of the following companies: Abbott, Abbvie, AstraZeneca, Bayer, BD, Boerhinger-Ingelheim, Eisai, Eli Lilly, GSK Janssen, Miravo Pharm, Moderna, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, Teva

However, while B12 injections or oral supplements are typically considered safe, there are significant risks when administered without proper preliminary testing

He added that this could come from neurological changes or changes in salivary production (many GLP-1 users report dry mouths)